Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance after first-line platinum chemotherapy for advanced urothelial cancer
NL-OMON55699Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Avelumab + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Overall survival. Started Mar 2017; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55699.